182 related articles for article (PubMed ID: 38557192)
1. Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancer.
He T; Cheng C; Qiao Y; Cho H; Young E; Mannan R; Mahapatra S; Miner SJ; Zheng Y; Kim N; Zeng VZ; Wisniewski JP; Hou S; Jackson B; Cao X; Su F; Wang R; Chang Y; Kuila B; Mukherjee S; Dukare S; Aithal KB; D S S; Abbineni C; Vaishampayan U; Lyssiotis CA; Parolia A; Xiao L; Chinnaiyan AM
Proc Natl Acad Sci U S A; 2024 Apr; 121(15):e2322563121. PubMed ID: 38557192
[TBL] [Abstract][Full Text] [Related]
2. Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancer.
He T; Cheng C; Qiao Y; Cho H; Young E; Mannan R; Mahapatra S; Miner SJ; Zheng Y; Kim N; Zeng VZ; Wisniewski JP; Hou S; Jackson B; Cao X; Su F; Wang R; Chang Y; Kuila B; Mukherjee S; Dukare S; Aithal KB; D S S; Abbineni C; Lyssiotis CA; Parolia A; Xiao L; Chinnaiyan AM
bioRxiv; 2024 Mar; ():. PubMed ID: 38464081
[TBL] [Abstract][Full Text] [Related]
3. Targeting SWI/SNF ATPases in enhancer-addicted prostate cancer.
Xiao L; Parolia A; Qiao Y; Bawa P; Eyunni S; Mannan R; Carson SE; Chang Y; Wang X; Zhang Y; Vo JN; Kregel S; Simko SA; Delekta AD; Jaber M; Zheng H; Apel IJ; McMurry L; Su F; Wang R; Zelenka-Wang S; Sasmal S; Khare L; Mukherjee S; Abbineni C; Aithal K; Bhakta MS; Ghurye J; Cao X; Navone NM; Nesvizhskii AI; Mehra R; Vaishampayan U; Blanchette M; Wang Y; Samajdar S; Ramachandra M; Chinnaiyan AM
Nature; 2022 Jan; 601(7893):434-439. PubMed ID: 34937944
[TBL] [Abstract][Full Text] [Related]
4. Targeting the mSWI/SNF Complex in POU2F-POU2AF Transcription Factor-Driven Malignancies.
He T; Xiao L; Qiao Y; Klingbeil O; Young E; Wu XS; Mannan R; Mahapatra S; Eyunni S; Tien JC; Wang X; Zheng Y; Kim N; Zheng H; Hou S; Su F; Miner SJ; Mehra R; Cao X; Sekhar AC; Samajdar S; Ramachandra M; Parolia A; Vakoc CR; Chinnaiyan AM
bioRxiv; 2024 Jan; ():. PubMed ID: 38328238
[TBL] [Abstract][Full Text] [Related]
5. Targeting SWI/SNF ATPases in H3.3K27M diffuse intrinsic pontine gliomas.
Mota M; Sweha SR; Pun M; Natarajan SK; Ding Y; Chung C; Hawes D; Yang F; Judkins AR; Samajdar S; Cao X; Xiao L; Parolia A; Chinnaiyan AM; Venneti S
Proc Natl Acad Sci U S A; 2023 May; 120(18):e2221175120. PubMed ID: 37094128
[TBL] [Abstract][Full Text] [Related]
6. Mammalian SWI/SNF chromatin remodeling complexes promote tyrosine kinase inhibitor resistance in EGFR-mutant lung cancer.
de Miguel FJ; Gentile C; Feng WW; Silva SJ; Sankar A; Exposito F; Cai WL; Melnick MA; Robles-Oteiza C; Hinkley MM; Tsai JA; Hartley AV; Wei J; Wurtz A; Li F; Toki MI; Rimm DL; Homer R; Wilen CB; Xiao AZ; Qi J; Yan Q; Nguyen DX; Jänne PA; Kadoch C; Politi KA
Cancer Cell; 2023 Aug; 41(8):1516-1534.e9. PubMed ID: 37541244
[TBL] [Abstract][Full Text] [Related]
7. Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatment.
Kregel S; Wang C; Han X; Xiao L; Fernandez-Salas E; Bawa P; McCollum BL; Wilder-Romans K; Apel IJ; Cao X; Speers C; Wang S; Chinnaiyan AM
Neoplasia; 2020 Feb; 22(2):111-119. PubMed ID: 31931431
[TBL] [Abstract][Full Text] [Related]
8. The ATPase module of mammalian SWI/SNF family complexes mediates subcomplex identity and catalytic activity-independent genomic targeting.
Pan J; McKenzie ZM; D'Avino AR; Mashtalir N; Lareau CA; St Pierre R; Wang L; Shilatifard A; Kadoch C
Nat Genet; 2019 Apr; 51(4):618-626. PubMed ID: 30858614
[TBL] [Abstract][Full Text] [Related]
9. The Bromodomains of the mammalian SWI/SNF (mSWI/SNF) ATPases Brahma (BRM) and Brahma Related Gene 1 (BRG1) promote chromatin interaction and are critical for skeletal muscle differentiation.
Sharma T; Robinson DCL; Witwicka H; Dilworth FJ; Imbalzano AN
Nucleic Acids Res; 2021 Aug; 49(14):8060-8077. PubMed ID: 34289068
[TBL] [Abstract][Full Text] [Related]
10. Residual complexes containing SMARCA2 (BRM) underlie the oncogenic drive of SMARCA4 (BRG1) mutation.
Wilson BG; Helming KC; Wang X; Kim Y; Vazquez F; Jagani Z; Hahn WC; Roberts CW
Mol Cell Biol; 2014 Mar; 34(6):1136-44. PubMed ID: 24421395
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological disruption of mSWI/SNF complex activity restricts SARS-CoV-2 infection.
Wei J; Patil A; Collings CK; Alfajaro MM; Liang Y; Cai WL; Strine MS; Filler RB; DeWeirdt PC; Hanna RE; Menasche BL; Ökten A; Peña-Hernández MA; Klein J; McNamara A; Rosales R; McGovern BL; Luis Rodriguez M; García-Sastre A; White KM; Qin Y; Doench JG; Yan Q; Iwasaki A; Zwaka TP; Qi J; Kadoch C; Wilen CB
Nat Genet; 2023 Mar; 55(3):471-483. PubMed ID: 36894709
[TBL] [Abstract][Full Text] [Related]
12. Synthetic lethality: targeting SMARCA2 ATPase in SMARCA4-deficient tumors - a review of patent literature from 2019-30 June 2023.
Reichl KD; Lee ECY; Gopalsamy A
Expert Opin Ther Pat; 2024 Mar; 34(3):159-169. PubMed ID: 38578210
[TBL] [Abstract][Full Text] [Related]
13. Targeting androgen receptor and the variants by an orally bioavailable Proteolysis Targeting Chimeras compound in castration resistant prostate cancer.
Hung CL; Liu HH; Fu CW; Yeh HH; Hu TL; Kuo ZK; Lin YC; Jhang MR; Hwang CS; Hsu HC; Kung HJ; Wang LY
EBioMedicine; 2023 Apr; 90():104500. PubMed ID: 36893587
[TBL] [Abstract][Full Text] [Related]
14. A selective and orally bioavailable VHL-recruiting PROTAC achieves SMARCA2 degradation in vivo.
Kofink C; Trainor N; Mair B; Wöhrle S; Wurm M; Mischerikow N; Roy MJ; Bader G; Greb P; Garavel G; Diers E; McLennan R; Whitworth C; Vetma V; Rumpel K; Scharnweber M; Fuchs JE; Gerstberger T; Cui Y; Gremel G; Chetta P; Hopf S; Budano N; Rinnenthal J; Gmaschitz G; Mayer M; Koegl M; Ciulli A; Weinstabl H; Farnaby W
Nat Commun; 2022 Oct; 13(1):5969. PubMed ID: 36216795
[TBL] [Abstract][Full Text] [Related]
15. Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancers.
Cantley J; Ye X; Rousseau E; Januario T; Hamman BD; Rose CM; Cheung TK; Hinkle T; Soto L; Quinn C; Harbin A; Bortolon E; Chen X; Haskell R; Lin E; Yu SF; Del Rosario G; Chan E; Dunlap D; Koeppen H; Martin S; Merchant M; Grimmer M; Broccatelli F; Wang J; Pizzano J; Dragovich PS; Berlin M; Yauch RL
Nat Commun; 2022 Nov; 13(1):6814. PubMed ID: 36357397
[TBL] [Abstract][Full Text] [Related]
16. Dual loss of the SWI/SNF complex ATPases SMARCA4/BRG1 and SMARCA2/BRM is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type.
Karnezis AN; Wang Y; Ramos P; Hendricks WP; Oliva E; D'Angelo E; Prat J; Nucci MR; Nielsen TO; Chow C; Leung S; Kommoss F; Kommoss S; Silva A; Ronnett BM; Rabban JT; Bowtell DD; Weissman BE; Trent JM; Gilks CB; Huntsman DG
J Pathol; 2016 Feb; 238(3):389-400. PubMed ID: 26356327
[TBL] [Abstract][Full Text] [Related]
17. PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer.
Raina K; Lu J; Qian Y; Altieri M; Gordon D; Rossi AM; Wang J; Chen X; Dong H; Siu K; Winkler JD; Crew AP; Crews CM; Coleman KG
Proc Natl Acad Sci U S A; 2016 Jun; 113(26):7124-9. PubMed ID: 27274052
[TBL] [Abstract][Full Text] [Related]
18. Antiandrogens Inhibit ABCB1 Efflux and ATPase Activity and Reverse Docetaxel Resistance in Advanced Prostate Cancer.
Zhu Y; Liu C; Armstrong C; Lou W; Sandher A; Gao AC
Clin Cancer Res; 2015 Sep; 21(18):4133-42. PubMed ID: 25995342
[TBL] [Abstract][Full Text] [Related]
19. Ovarian high-grade serous carcinoma cells with low SMARCA4 expression and high SMARCA2 expression contribute to platinum resistance.
Kido K; Nojima S; Motooka D; Nomura Y; Kohara M; Sato K; Ohshima K; Tahara S; Kurashige M; Umeda D; Takashima T; Kiyokawa H; Ukon K; Matsui T; Okuzaki D; Morii E
J Pathol; 2023 May; 260(1):56-70. PubMed ID: 36763038
[TBL] [Abstract][Full Text] [Related]
20. Discovery of SMD-3040 as a Potent and Selective SMARCA2 PROTAC Degrader with Strong
Yang L; Tu W; Huang L; Miao B; Kaneshige A; Jiang W; Leng L; Wang M; Wen B; Sun D; Wang S
J Med Chem; 2023 Aug; 66(15):10761-10781. PubMed ID: 37523716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
